Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2011 May;37(3):242-9. doi: 10.1016/j.ctrv.2010.07.005. Epub 2010 Aug 14.

Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.

Author information

  • 1Southampton Health Technology Assessments Centre, University of Southampton, First Floor Epsilon House, Enterprise Road, Southampton Science Park, Southampton, UK. d.hartwell@soton.ac.uk

Abstract

BACKGROUND:

Topotecan is a relatively new drug for use as a second-line treatment in patients with relapsed small cell lung cancer (SCLC). We performed a systematic review and economic evaluation of topotecan, and consider it here in relation to the NICE end of life criteria.

METHODS:

Seventeen bibliographic databases (including Cochrane library, Medline and Embase) were searched from 1990 to February 2009, and experts and manufacturers were consulted, to identify relevant randomised controlled trials (RCTs) which were selected according to prospectively defined criteria. An economic evaluation was undertaken to assess cost effectiveness compared with best supportive care (BSC) in the UK.

RESULTS:

Five RCTs were included. The clinical evidence indicates a statistically significant benefit of oral topotecan plus BSC compared to BSC alone for overall survival. Intravenous topotecan was similar in efficacy to both oral topotecan and CAV (cyclophosphamide, doxorubicin and vincristine). In the survival model, oral topotecan plus BSC was associated with an average gain in life expectancy of approximately 4 months, resulting in a gain of 0.183 quality-adjusted life years (QALYs). At an incremental cost of approximately £6200 the incremental cost effectiveness ratio (ICER) is £33,851 per QALY gained.

CONCLUSIONS:

Compared with BSC alone, oral topotecan for patients with relapsed SCLC was associated with improved health outcomes but at increased cost. The ICER is at the upper extreme of the range conventionally regarded as cost effective from an NHS decision making perspective. However, this treatment may fall under supplementary guidance for life extending, end of life treatments.

Crown Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

PMID:
20709456
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk